The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Abbott Laboratories

NYSE: ABT
Last

(U.S.) $49.03

Today's change-0.31 -0.63%
Updated May 22 4:01 PM EDT. Delayed by at least 15 minutes.
 

Abbott Laboratories

NYSE: ABT
Last

(U.S.) $49.03

Today's change-0.31 -0.63%
Updated May 22 4:01 PM EDT. Delayed by at least 15 minutes.

Reversal following new 52-week high

Abbott Laboratories closed lower Friday, dropping (U.S.)$0.31 or 0.63% to (U.S.)$49.03 after setting a new 52-week high. Over the last five days, shares have gained 0.66% and 8.91% year to date. Shares have outperformed the S&P 500 by 11.32% during the last year.

Key company metrics

  • Open(U.S.) $49.10
  • Previous close(U.S.) $49.34
  • High(U.S.) $49.43
  • Low(U.S.) $48.91
  • Bid / Ask-- / --
  • YTD % change+8.91%
  • Volume3,454,659
  • Average volume (10-day)4,281,818
  • Average volume (1-month)4,452,835
  • Average volume (3-month)4,753,398
  • 52-week range(U.S.) $39.24 to (U.S.) $49.43
  • Beta0.64
  • Trailing P/E36.73×
  • P/E 1 year forward22.72×
  • Forward PEG2.47×
  • Indicated annual dividend(U.S.) $0.96
  • Dividend yield1.96%
  • Trailing EPS(U.S.) $1.33
Updated May 22 4:01 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+9.94%

Based on its net profit margin of 9.94%, Abbott Laboratories is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.02%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue4,8975,2905,1045,551
Total other revenue--------
Total revenue4,8975,2905,1045,551
Gross profit2,8172,9862,7783,048
Total cost of revenue2,0802,3042,3262,503
Total operating expense4,2874,4814,3734,790
Selling / general / administrative1,7301,7131,5661,737
Research & development313346305335
Depreciation / amortization156163132161
Interest expense (income), net operating--------
Unusual expense (income)8-454451
Other operating expenses, total--------
Operating income610809731761
Interest income (expense), net non-operating-37-43-35--
Gain (loss) on sale of assets--------
Other--------
Income before tax653802718737
Income after tax529632440460
Income tax, total124170278277
Net income2,292904538466
Total adjustments to net income--------
Net income before extra. items529632440460
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items529632440460
Inc. avail. to common incl. extra. items2,292904538466
Diluted net income2,292904538466
Dilution adjustment------0
Diluted weighted average shares1,5161,5221,5201,517
Diluted EPS excluding extraordinary itemsvalue per share0.350.420.290.30
Dividends per sharevalue per share0.240.240.220.22
Diluted normalized EPSvalue per share0.350.390.310.32